Myriad Genetics (STU:MYD) Cyclically Adjusted Book per Share: €11.30 (As of Mar. 2026)


STU:MYD Myriad Genetics Inc STU:MYD
49 GF Score
Price €5.30
GF Value €13.30
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Cyclically Adjusted Book per Share?

Myriad Genetics STU:MYD +2.91% 49 Cyclically Adjusted Book per Share is €11.30 as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 49/100 and a GF Value™ of €13.30 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Myriad Genetics's adjusted book value per share for the three months ended in Mar. 2026 was €3.092. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.30 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Myriad Genetics's average Cyclically Adjusted Book Growth Rate was -4.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -0.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 3.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Myriad Genetics was 12.20% per year. The lowest was -0.90% per year. And the median was 10.85% per year.

As of today (2026-07-07), Myriad Genetics's current stock price is €5.30. Myriad Genetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €11.30. Myriad Genetics's Cyclically Adjusted PB Ratio of today is 0.47.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Myriad Genetics was 5.34. The lowest was 0.27. And the median was 1.95.


Myriad Genetics  (STU:MYD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Myriad Genetics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.30/11.30
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Myriad Genetics was 5.34. The lowest was 0.27. And the median was 1.95.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Myriad Genetics Cyclically Adjusted Book per Share Related Terms


Myriad Genetics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Cyclically Adjusted Book per Share Chart

Myriad Genetics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.08 12.68 12.75 12.69 11.38

Myriad Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.63 11.52 11.40 11.38 11.30

STU:MYD vs FLGT, CSTL, BDSX: Cyclically Adjusted Book per Share Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted PB Ratio falls into.


STU:MYD
49GF Score
Myriad Genetics Inc STU:MYD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Myriad Genetics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.092/330.2130*330.2130
=3.092

Current CPI (Mar. 2026) = 330.2130.

Myriad Genetics Quarterly Data

Book Value per Share CPI Adj_Book
201606 9.635 241.018 13.201
201609 9.581 241.428 13.104
201612 10.202 241.432 13.954
201703 10.273 243.801 13.914
201706 9.998 244.955 13.478
201709 10.559 246.819 14.127
201712 11.131 246.524 14.910
201803 11.010 249.554 14.569
201806 11.714 251.989 15.350
201809 12.645 252.439 16.541
201812 12.779 251.233 16.796
201903 13.044 254.202 16.944
201906 13.111 256.143 16.902
201909 13.114 256.759 16.866
201912 13.013 256.974 16.722
202003 11.749 258.115 15.031
202006 10.915 257.797 13.981
202009 10.266 260.280 13.024
202012 9.605 260.474 12.177
202103 9.585 264.877 11.949
202106 9.641 271.696 11.717
202109 10.330 274.310 12.435
202112 10.706 278.802 12.680
202203 10.784 287.504 12.386
202206 11.120 296.311 12.392
202209 11.443 296.808 12.731
202212 10.298 296.797 11.457
202303 9.571 301.836 10.471
202306 8.286 305.109 8.968
202309 7.803 307.789 8.371
202312 7.989 306.746 8.600
202403 7.726 312.332 8.168
202406 7.568 314.175 7.954
202409 7.245 315.301 7.588
202412 7.334 315.605 7.673
202503 7.072 319.799 7.302
202506 3.614 322.561 3.700
202509 3.414 324.800 3.471
202512 3.361 324.054 3.425
202603 3.092 330.213 3.092

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €11.30 mean?
Myriad Genetics (STU:MYD) has a Cyclically Adjusted Book per Share of €11.30 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Cyclically Adjusted Book per Share too high?
Myriad Genetics' current Cyclically Adjusted Book per Share is €11.30. Overall, Myriad Genetics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Cyclically Adjusted Book per Share compare to FLGT and CSTL?
Myriad Genetics' Cyclically Adjusted Book per Share of €11.30 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Book per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Cyclically Adjusted Book per Share is €11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.30, compared to a current price of €5.30 — trading 60.2% below its estimated fair value. The current Cyclically Adjusted Book per Share is €11.30. Myriad Genetics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Cyclically Adjusted Book per Share is €11.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.30 is trading 60.2% below its estimated GF Value™ of €13.30. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Cyclically Adjusted Book per Share: €11.30
  • GF Value™: €13.30 vs. price of €5.30 (60.2% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
49GF Score

Get the complete analysis for STU:MYD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.30
Price
€13.30
GF Value